Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.
J Infect Public Health
; 14(5): 655-660, 2021 May.
Article
en En
| MEDLINE
| ID: mdl-33857725
ABSTRACT
The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19 by interfering with key steps in the virus replication cycle. It is considered a therapeutic option to be evaluated against COVID-19, based on data on its in vitro and in vivo activity against MERS-CoV and SARS-CoV coronaviruses. In this work, we provide an overview of remdesivir's discovery, mechanism of action, and the current studies exploring its clinical effectiveness. Recommendations for its use against COVID-19 infection are also summarized.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article